These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

763 related items for PubMed ID: 15612981

  • 61. Calcineurin inhibitor-free immunosuppression based on antithymocyte globulin and mycophenolate mofetil in cadaveric kidney transplantation: results after 5 years.
    Grinyó JM, Gil-Vernet S, Cruzado JM, Caldés A, Riera L, Serón D, Rama I, Torras J.
    Transpl Int; 2003 Nov; 16(11):820-7. PubMed ID: 12879230
    [Abstract] [Full Text] [Related]

  • 62. Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.
    Budde K, Bosmans JL, Sennesael J, Zeier M, Pisarski P, Schütz M, Fischer W, Neumayer HH, Glander P.
    Clin Nephrol; 2007 Mar; 67(3):164-75. PubMed ID: 17390741
    [Abstract] [Full Text] [Related]

  • 63. Basiliximab induction in renal transplantation: long-term outcome.
    Atlani M, Sharma RK, Gupta A.
    Saudi J Kidney Dis Transpl; 2013 May; 24(3):473-9. PubMed ID: 23640617
    [Abstract] [Full Text] [Related]

  • 64. Successful withdrawal of steroids in pediatric renal transplant recipients receiving cyclosporine A and mycophenolate mofetil treatment: results after four years.
    Höcker B, John U, Plank C, Wühl E, Weber LT, Misselwitz J, Rascher W, Mehls O, Tönshoff B.
    Transplantation; 2004 Jul 27; 78(2):228-34. PubMed ID: 15280683
    [Abstract] [Full Text] [Related]

  • 65. Cyclosporine-sparing effect of basiliximab in renal transplant recipients with mycophenolate mofetil.
    Tojimbara T, Sato S, Koyama I, Nanmoku K, Sekijima M, Tonsyo M, Kai K, Kato Y, Urashima Y, Nakajima I, Fuchinoue S, Teraoka S.
    Transplant Proc; 2005 Mar 27; 37(2):895-8. PubMed ID: 15848568
    [Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 69. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol.
    Jaber JJ, Feustel PJ, Elbahloul O, Conti AD, Gallichio MH, Conti DJ.
    Clin Transplant; 2007 Mar 27; 21(1):101-9. PubMed ID: 17302598
    [Abstract] [Full Text] [Related]

  • 70.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 71. Decreased incidence of acute rejection in adolescent kidney transplant recipients using antithymocyte induction and triple immunosuppression.
    Schwartz JJ, Ishitani MB, Weckwerth J, Morgenstern B, Milliner D, Stegall MD.
    Transplantation; 2007 Sep 27; 84(6):715-21. PubMed ID: 17893604
    [Abstract] [Full Text] [Related]

  • 72. Early steroid withdrawal in a renal transplant cohort treated with tacrolimus, mycophenolate mofetil and basiliximab.
    Andrade-Sierra J, Rojas-Campos E, Cardona-Muñoz E, Evangelista-Carrillo LA, Puentes-Camacho A, Lugo-López O, Gómez B, Valdespino C, Cerrillos I, Medina-Pérez M, Jalomo B, Nieves JJ, Sandoval M, Ramos-Solano F, Monteón-Ramos F, Cueto-Manzano AM.
    Nefrologia; 2014 Sep 27; 34(2):216-22. PubMed ID: 24658197
    [Abstract] [Full Text] [Related]

  • 73. Tacrolimus, Mycophenolate Mofetil, and Low-Dose Steroids With or Without Interleukin-2 Receptor Antibody Induction Therapy: A Retrospective Cohort Analysis.
    Schwarz C, Böhmig G, Steininger R, Unger L, Kristo I, Kozakowski N, Berlakovich GA, Soliman T, Mühlbacher F.
    Transplant Proc; 2015 Oct 27; 47(8):2446-9. PubMed ID: 26518948
    [Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76. Induction antibody therapy in renal transplantation using early steroid withdrawal: long-term results comparing anti-IL2 receptor and anti-thymocyte globulin.
    Libório AB, Mendoza TR, Esmeraldo RM, Oliveira ML, Paes FJ, Silva Junior GB, Daher EF.
    Int Immunopharmacol; 2011 Nov 27; 11(11):1832-6. PubMed ID: 21835269
    [Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78. Daclizumab induction as an immunosuppressive regimen for renal transplant recipients from non-heart-beating donors.
    Sánchez-Fructuoso AI, Prats D, Marques M, Ridao N, Conesa J, García Mena M, Torrente J, Barrientos A.
    Transplant Proc; 2003 Aug 27; 35(5):1689-90. PubMed ID: 12962759
    [Abstract] [Full Text] [Related]

  • 79. Low-dose RATG with or without basiliximab in renal transplantation: a matched-cohort observational study.
    Gentile G, Somma C, Gennarini A, Mastroluca D, Rota G, Lacanna F, Locatelli B, Remuzzi G, Ruggenenti P.
    Am J Nephrol; 2015 Aug 27; 41(1):16-27. PubMed ID: 25612603
    [Abstract] [Full Text] [Related]

  • 80. Prospective controlled protocol for three months steroid withdrawal with tacrolimus, basiliximab, and mycophenolate mofetil in renal transplant recipients.
    Oh CK, Kim SJ, Kim JH, Lee JH.
    J Korean Med Sci; 2012 Apr 27; 27(4):337-42. PubMed ID: 22468094
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 39.